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78 Poster Session-IMethods: The surveyed centers accounted for 75% of all pediat-
ric HSCT and were identified by querying the CIBMTR. Two indi-
viduals from each of these institutions were survey recipients; one
from the Division of Pediatric Critical Care Medicine (PCCM)
and the other from the Division of HSCT. The survey was con-
ducted electronically using SurveyMonkey allowing data to remain
anonymous. A four-choice Lickert scale was used for clinical ques-
tions.
Results: Completed surveys were returned from both the HSCT
and PCCM physicians in 22 programs. The percentage of programs
that always or commonly perform the following interventions on the
HSCT unit are as follows: central venous pressure monitoring
(18%), 100% non-rebreather mask (50%), non-invasive ventila-
tion(18%), intermittent hemodialysis (41%), continuous veno-
venous hemofiltration (0%), dopamine (36%) with the maximal
dose varying by center. In terms of care by PCCM physicians,
most all programs use 100% oxygen, non-invasive ventilation and
aggressive diuresis prior to intubation; 2/3 of programs attempt renal
replacement therapy (RRT). 59% of PCCM physicians always or
commonly offer intubation as a time limited trial to HSCT patients;
18% never offer this option. Non-conventional respiratory therapies
commonly offered to HSCT patients include high frequency oscilla-
tory ventilation, nitric oxide and RRT. Surfactant use is less common
and ECMO use is rare.
Conclusion: There is a notable variation in the level of monitor-
ing and support offered on pediatric HSCT units as well as therapies
provided by PCCM physicians to HSCT patients. Not only is this
data is important for the design of clinical trials, but studies should
be done to determine if these practice variations impact patient out-
comes.211
SURVIVAL FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION
FOR CONGENITAL IMMUNODEFICIENCY AND METABOLIC DISORDERS
Horwitz, M.E.1, Tunes da Silva, G.2, Eapen, M.2, Horwitz, E.M.3 1 Duke
University Medical Center, Durham, NC; 2 Medical College of Wisconsin,
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We compared outcomes of allogeneic stem cell transplantation
(SCT) for congenital immunodeficiency and metabolic disorders
to children of a similar age who received SCT for acute leukemia
in first or second complete remission. This analysis was undertaken
to address a reluctance among many physicians to refer children
with certain congenital immunodeficiency or metabolic disorders
for early SCT. The study population includes 343 children (#5
years) with congenital immunodeficiency (129 with severe com-
bined immunodeficiency [SCID]; 214 with non-SCID) and 354
children with metabolic disorders. This population was compared
to 622 age-matched children with acute leukemia (the control pop-
ulation). All transplantations occurred between 1995 and 2005 and
the transplant conditioning regimen was myeloablative. In univari-
ate analysis, 5-year overall survival was higher after HLA-matched
sibling donor transplants for SCID (80%), non-SCID (84%) and
metabolic disorders (78%) compared to the control group (51%,
p\0.001). Amongst recipients of unrelated donor SCT, 5-year
overall survival was higher for non-SCID patients compared to con-
trols (66% vs 50%, p5 0.05). The 5-year survival rates were similar
after unrelated donor SCT for SCID (41%), metabolic (51%) and
good risk acute leukemia, the control group (50%). In multivariate
analysis, donor type was the only factor associated with survival;
mortality rates were higher after unrelated donor SCT (odds ratio
1.49, 95% CI 1.02–2.16, p 5 0.04). Further, we observed no differ-
ences in survival after unrelated donor bone marrow and cord blood
SCT. The data suggest children with congenital immunodeficiency
and metabolic disorders who receive an unrelated donor SCT have
similar survival rates as children with good risk acute leukemia. The
sub-group of children with non-SCID diseases fare the best, with
a 5-year overall survival that exceeds that of age-matched patients
with acute leukemia. Therefore prompt referral for SCT for these
children, before mounting comorbidities render them ineligible,
should be encouraged even in the absence of an HLA-matched sib-
ling donor.212
REDUCED TOXICITY MYELOABLATIVE CONDITIONING REGIMEN WITH
BUSULFAN, FLUDARABINE AND ALEMTUZUMAB FOR CHILDREN
WITH NON-MALIGNANT DISORDERS, MYELODYSPLASTIC SYNDROME
(MDS) AND MYELOID MALIGNANCIES
Horn, B.N., Dvorak, C.C., Huang, J., Englert, L., Kavanau, K.,
Cowan, M.J. University of California San Francisco, San Francisco, CA
Major problems with Busulfan/Cyclophosphamide (Bu/Cy) con-
ditioning are acute toxicities and graft failure. In 2000, we replaced
Bu/Cy conditioning with targeted i.v. Busulfan/Fludarabine/rabbit
ATG (Bu/Flu/rATG) which effectively reduced acute toxicities;
however, graft failure rate remained high (21%). In 2004, we intro-
duced targeted i.v. Busulfan/Fludarabine and Alemtuzumab (Bu/
Flu/Campath) to reduce graft failure rate. We describe and compare
the outcomes of the first 21 Bu/Flu/Campath study patients (median
age 8, range 1–16 years) with those of previously published 19 By/
Flu/rATG study patients. Diagnoses included MDS or myeloid ma-
lignancy (N 5 5), hemoglobinopathy (N 5 3), non-SCID primary
immunodeficiency (N 5 6), aplastic anemia (N 5 2), autoimmune
disorders (N 5 2), and metabolic disorders (N 5 3). The donors
included$8/8 HLA-matched (N 5 6) and one antigen mismatched
(N 5 4) unrelated volunteers, and fully matched related donors
(N 5 11). Stem cell sources were peripheral blood (N 5 9), bone
marrow (N 5 10) or combined sources (N 5 2). 19/20 evaluable
patients engrafted. One patient withHurler’s disease developed graft
rejection 40 days post transplant but was rescued with a 2nd trans-
plant. The median follow-up of living patients is 21 months (range
4.3–51 months). Estimated 2-year post-transplant overall and
event-free survival rates were 83 6 9% and 71 6 11%, respectively,
which is similar to survival in the Bu/Flu/rATG study (896 7% and
74 6 10%). Three patients died (at 1, 5, and 12 months post trans-
plant) due to intracranial hemorrhage in 1 patient with Evans
syndrome, Aspergillus infection and GVHD in 1 patient with adre-
nal leukodystrophy (ALD), and disease progression and GVHD in 1
patient with ALD. One patient with MDS relapsed 1 year following
the transplant, but is alive following the 2nd successful transplant.
CMV reactivated in 47% (7/15) patients who were at risk for reacti-
vation and was successfully treated in all. Only 1 patient developed
mild VOD (maximum total bilirubin 3.4 mg/dl). The incidence of
acute and chronic GVHDwas 15% each, respectively. At last follow
up 85% of patients remain mixed chimeras. Bu/Flu/Campath condi-
tioning was well tolerated and resulted in durable mixed chimerism
in the majority of patients. Compared with Bu/Flu/rATG, Bu/Flu/
Campath conditioning resulted in significantly reduced graft rejec-
tion rate (2-tailed Fisher’s exact p 5 0.03) in mismatched MUD
transplants, but it did not improve overall survival or event free-
survival.213
SECOND ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IN PEDIAT-
RIC PATIENTS
Ayas, M.1, Al-Jefri, A.1, Eldali, A.2, Al-seraihi, A.1, Al-Mahr, M.1, Al-
Ghonaium, A.3, Al-Ahmari, A.1, Al-Mousa, H.3, Al-Mohsen, S.3, Al-
Dhekri, H.3, El-Solh, H.1 1 King Faisal Specialist Hospital & Research
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Graft rejection and/or disease relapse after allogeneic SCT are
ominous events that are often associated with dismal outcome; sec-
ond SCTmay be considered as a salvage alternative in these patients
(pts) but is generally regarded as a procedure that is associated with
high morbidity and mortality. In the pediatric population, the data
on the outcome of second SCT are sketchy and scarce. We present
here our experience in 51 pediatric pts who underwent a second
SCT at our institution (KFSHRC).
Patients and methods: From May 1996 until May 2008, 51 pts
with graft failure or disease relapse after SCT (24 females and 27
males) underwent second SCT at KFSHRC; 17 pts had leukemia,
16 pts had non-malignant hematological disorders (NMHD), 16
pts had immune deficiency disorders (IMD), and 2 pts had meta-
bolic disorders. 35 pts were reconditioned with myeloablative reg-
imens (including 19 pts with TBI-regimens), 7 pts with
Poster Session-I 79serotherapy alone, 6 pts with reduced intensity regimens, and 3
pts received no conditioning. Median age at the second SCT
was 6.2 years (range, 0.3–14.2 years) and the median time from
the first SCT to the second SCT was 10.3 months (range, 1.2–
84 months).
Results: 40 patients had initial engraftment, median time to ANC
$ 500  106/l was 19 days (range, 9–28 days), and median time to
a platelet count $ 20  109/l was 26.5 days (range, 10–100 days).
Acute grade $ 3 GVHD, developed in 7 pts (13.7%), mild VOD
of the liver developed in 2 pts (3.9%).The 10-year overall (OS) and
event free survival (EFS) were 66% and 50% respectively.When sur-
vival was evaluated by the interval between the 1st and 2nd SCT:\6
months (19 pts) and $ 6 months (32 pts), the 10-year OS was 55%
and 73% for the 2 cohorts respectively (P 5 0.05), and the 10-year
EFS was 27% and 67% for the 2 cohorts respectively (P 5 0.005).
With intervals of\ 12 months (26 pts) and $ 12 months (25 pts),
the 10-year OS was 64% and 70% for the 2 cohorts respectively
(P 5 0.4), and the 10-year EFS was 42% and 63% for the 2 cohorts
respectively (P 5 0.2). When survival was evaluated by underlying
disease, the 10-year OS was 59%, 75% and 59% for pts
with NMHD, IMD and leukemia respectively (P 5 0.3), and the
10-year EFS was 55%, 50%, and 59% (P5 0.5) for the same groups
respectively.
Conclusions: Second SCT in children is relatively well tolerated
and is associated with reasonable survival. OS and EFS appear to be
considerably better when the interval between the 2 transplants is$
6 months.214
RESULTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PA-
TIENTS WITH LEUKOCYTE ADHESION DEFICIENCY TYPE I
Hamidieh, A.A.1, Pourpak, Z.2, Alimoghaddam, K.1, Ardalan, M.2,
Bahoush, G.3, Jalili, M.1, Movahedi, M.2, Moin, M.2,
Ghavamzadeh, A.1 1 Hematology-Oncology and Stem Cell Transplanta-
tion Research Center, Tehran, Islamic Republic of Iran; 2 Immunology,
Asthma & Allergy Research Institute, Tehran, Islamic Republic of Iran;
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Objective: Hematopoietic stem cell transplantation (HSCT) is
the only curative treatment of some congenital immunodefi-
ciency diseases especially leukocyte adhesion deficiency type-I
(LAD-I).
Methods: Six patients (3 girls, 3 boys), received allogeneic HSCT
between 2007 and 2008. One patient received stem cell from her
healthy full human leukocyte antigen (HLA) matched sibling, three
patients from their full matched other related (one from father, one
frommother and one from uncle which verified with high resolution
HLA matching method), one patient from his mother (haploidenti-
cal) and one patient from his father with one antigen mismatch. The
graft source was bone marrow in 4 patients and peripheral blood
stem cells (PBSC) in others. Median age at HSCT was 17 months
(10.2–87.8 months). All patients were conditioned with Fludarabine,
Melfalan and Antithymocyte globulin (ATG). For graft-versus-host
disease (GVHD) prophylaxis, we used Cyclosporine and Methyl-
prednisolone.
Results: All patients engrafted. Median time of Absolute Neutro-
phil Count $ 0.5109 /L was 113 and median time of Platelet re-
covery $20109 /L was 116. Median follow-up of patients was 8
months (range, 1–20 months) and at present five (83%) patients
are alive with sustained engraftment and without recurrent infection
and improvement of their failure to trive. Three patients developed
acute GVHD after transplantation that one of them died because of
acute GVHD one month after transplantation. No chronic GVHD
occurred. Full chimerism was achieved in one patient and mixed chi-
merism was achieved in four patients.
Conclusions: Early diagnosis and HSCT of LAD-I rescue
patients from lethal disease but not all of patients have full match
siblings and others must transplanted from other related, haploi-
dentical relative, non relative full match or cord blood. Analysis
of our patients who developed mixed chimerism suggested that
this mixed chimeric state resulted in a reversal of the LAD-I
phenotype.215
STABLE MIXED CHIMERISM AFTER NON-MYELOABLATIVE TRANSPLANT
FOR SICKLE CELL DISEASE: NORMAL HEMATOPOIESIS DOMINATES OVER
ABNORMAL IN MIXED CHIMERISM
Ildstad, S.1, Cheerva, A.2, Tollerud, D.1, Bertolone, S.2, Herzig, G.2,
Herzig, R.2 1 University of Louisville, Louisville, KY; 2 University of
Louisville, Louisville, KY
Allosensitization due to transfusion therapy has been a barrier to
engraftment in patients with sickle cell (SC) disease, requiring the
use of more intense conditioning. In a mouse model, sensitization
to bone marrow cells (BMC) results predominantly from the hu-
moral immune response. We added alemtuzumab (anti-CD52) lym-
phodepletion for conditioning recipients for a hematopoietic cell
transplant. 2 cycles of alemtuzumab were administered with the ra-
tionale of eliminating memory B cells by inducing them to undergo
homeostatic proliferation after the 1st round of depletion. Condi-
tioning consisted of alemtuzumab (10 mg/day, days -53— -50 and
days -24 —-21), fludarabine (30 mg/m2/day days -5 —-3), 200 cGy
TBI (day -1), matched related donor BM infusion day 0, followed
by cyclosporine and mycophenolate mofetil (day-1—.10 months).
2 patients have been transplanted. Patient 1 was 7 at transplant,
with a history of multiple pain crises, episodes of acute chest syn-
drome, and extensively treated with exchange transfusion therapy
and hydroxyurea. She received 14.5  106kg CD34 cells from her
HLA-identical sibling donor with SC trait, showing 78% donor en-
graftment day 30. Her RBC production remained phenotypically
trait which is compatible with donor hematopoiesis . 615 days
post-transplant, with donor lymphoid and myeloid chimerism con-
sistently 20–30%. Immunosuppression was discontinued 10 months
post-stem cell transplantation (SCT). Patient 2 was 9 at transplant
with multiple pain crises, 2 episodes of acute chest syndrome before
transplant, and had been treated with exchange transfusions for 7
years. He received HLA-matched sibling donor BM, processed to
deplete T- and B cells. The graft contained 5.24  106/kg CD34,
0.55  106/kg ab-TCR and 0.35  106/kg FC cells. He has been
transfusion-independent post-SCT, with 100% donor RBC produc-
tion and chimerism levels at 20–30% donor by FISH .851 days
post-transplant. Immunosuppression was discontinued at 23 months
post-SCT. Neither patient had GVHD, transplant-related toxicity,
or SC complications since transplant. Data suggest that the addition
of an alemtuzumab split-course to a nonmyeloablative transplant
regimen allows hematopoietic cell engraftment of allosensitized re-
cipients with SCD without GVHD. Stable mixed chimerism of my-
eloid and lymphoid lineages is accompanied by full donor
erythropoiesis. Stable mixed chimerismmay also have been achieved
due to prolonged post-SCT immunosuppression from MMF.216
BONE MINERAL DENSITY, LEAN BODY MASS, CALCIUM AND VITAMIN D
INTAKE IN CHILDREN AND ADOLESCENTS AFTER HEMATOPOIETIC STEM
CELL TRANSPLANTATION
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Introduction: Hematopoietic stem cell transplantation (HSCT)
has been associated with decreased food intake, malnutrition, re-
duced lean body mass and reduced bone mineral density (BMD),
which might result in increased morbidity and mortality. The pur-
pose of this study was to evaluate the BMD, lean body mass, calcium
and vitamin D intake in children and adolescents before and 6
months after HCT.
Patients andMethods:Forty patients (25 boys and 15 girls; mean
age: 10,16 4,26 yrs) who were consecutively submitted to allogenic
HSCT between September 2006 and March 2008 and survived after
6 months were included in the analysis. BMDwas evaluated by DXA
(HOLOGIC-1000) at the lumbar spine (LS) and whole body (WB),
lean body mass by bioelectrical impedance analysis and food intake
by a 24 hours recall and food frequency questionnaire.
Results: LS BMDwas 0,6736 0,167 g/cm2 in the first evaluation
and 0,6626 0,78 g/cm2 in the second evaluation (p. 0.05). TheWB
BMD was 0,850 6 0,164g/cm2 in the first evaluation, reducing to
